UK Cannabis Clinics

Published: 12 June 2026
Last Updated: 27 July 2026
Last Reviewed: 27 July 2026
Author: Weed Supermarket Editorial Team

What Thailand’s Cannabis U-Turn Means for Patients

Thailand’s cannabis policy has changed significantly since the country removed cannabis from its narcotics list in 2022.

The change led to rapid commercial expansion, with thousands of cannabis outlets opening in Bangkok, Phuket and other tourist areas. However, regulations governing recreational retail, prescribing, product standards and advertising did not develop at the same speed.

In June 2025, Thailand introduced tighter rules requiring a medical prescription for the purchase of cannabis flower and moved the market back towards medical and healthcare-focused access.

For patients researching a UK cannabis clinic, Thailand provides an important case study in what can happen when commercial access expands before a complete regulatory framework is established.

What Happened to Cannabis Law in Thailand?

Thailand became the first country in Asia to remove cannabis from its national narcotics list in June 2022.

The reform was intended to support:

Medical cannabis.
Traditional medicine.
Agricultural production.
Research.
Economic development.

However, the absence of comprehensive legislation governing recreational retail created a much broader consumer market than some policymakers had anticipated.

Cannabis outlets appeared rapidly across major cities and tourist destinations, often operating in a similar way to recreational dispensaries.

Was Recreational Cannabis Fully Legalised?

Thailand’s 2022 change was frequently described internationally as recreational legalisation, but the legal position was more complicated.

Cannabis was removed from the narcotics list, subject to restrictions on high-THC extracts, while public smoking could still be treated as a nuisance offence.

The country did not immediately introduce a complete adult-use framework covering:

Licensed recreational sales.
Product potency.
Age verification.
Advertising.
Packaging.
Retail zoning.
Consumer testing standards.

This regulatory gap allowed commercial activity to expand while political disagreement continued over the intended purpose of the reform.

Thailand’s Rapid Cannabis Retail Boom

Following the 2022 change, thousands of cannabis businesses opened across Thailand.

These included:

Retail dispensaries.
Cannabis cafés.
Tourist-focused shops.
Cultivation businesses.
Product manufacturers.
Delivery and online services.

The industry attracted domestic entrepreneurs and international investment, while cannabis became increasingly visible within tourism areas.

Supporters argued that the sector created jobs, supported farmers and generated economic activity.

Critics raised concerns about youth access, tourist consumption, advertising, inconsistent product standards and the absence of sufficient medical oversight.

Why Did Thailand Change Direction?

Political support for the original reform was not consistent across Thailand’s governing parties.

As the market expanded, the government faced increasing pressure to clarify whether cannabis should operate primarily as:

A medical treatment.
A traditional medicine.
An agricultural commodity.
A regulated recreational product.

Concerns were also raised about:

Sales without medical assessment.
Access by young people.
Unrestricted dispensary growth.
Public consumption.
Online sales.
Product quality and traceability.
Cross-border smuggling.

The eventual response was to strengthen medical controls rather than establish an unrestricted recreational retail model.

Thailand’s Medical-Prescription Requirement

New rules introduced in June 2025 classified cannabis flower as a controlled herb and required purchasers to have a prescription or medical certificate issued by an appropriately licensed Thai healthcare practitioner.

The rules were designed to restrict cannabis flower to medical use.

Prescribers may include authorised professionals working within:

Modern medicine.
Thai traditional medicine.
Applied Thai traditional medicine.
Traditional Chinese medicine.
Dentistry in appropriate circumstances.

Prescriptions are intended to cover limited personal medical use rather than unrestricted recreational purchasing.

What Changed for Thai Cannabis Shops?

Retailers wishing to continue supplying cannabis flower became subject to stricter requirements.

Depending on the business and product, these requirements may include:

Valid controlled-herb licensing.
Medical prescriptions before flower sales.
Supply from certified sources.
Transaction and stock records.
Limits on advertising.
Restrictions on online or vending-machine sales.
Medical or pharmacy involvement.
Compliance with location and operational standards.

Shops built around walk-in recreational sales faced the greatest challenge adapting to the new model.

Did More Than 7,000 Thai Cannabis Shops Close?

Officially reported figures showed substantial contraction within the licensed retail market.

Of 8,636 cannabis-shop licences that expired during 2025, only 1,339 renewal applications were submitted. The remaining 7,297 businesses did not seek renewal and were reported as ceasing operation under those licences.

This does not mean that every cannabis outlet in Thailand closed. Thousands of licensed businesses remained active, while some operators changed their services or attempted to comply with the medical requirements.

The figures nevertheless illustrate how quickly regulatory change can affect a rapidly expanded market.

What Is a UK Cannabis Clinic?

A UK cannabis clinic is a specialist healthcare service that assesses whether a patient may be suitable for treatment with a cannabis-based medicinal product.

Most clinics operate privately because NHS access remains limited.

A clinic may provide:

An initial eligibility assessment.
Review of medical records.
A specialist consultation.
A clinical prescribing decision.
Follow-up appointments.
Monitoring of side effects and treatment response.
Coordination with an authorised pharmacy.

A cannabis clinic is not a recreational dispensary and should not operate like an ordinary online cannabis retailer.

Is Medical Cannabis Legal in the UK?

Certain cannabis-based medicinal products have been available under specialist prescription since November 2018.

A prescribing decision must be made by an appropriately qualified clinician, generally a doctor on the General Medical Council’s Specialist Register or another prescriber acting within an appropriate specialist framework.

The 2018 change did not legalise recreational cannabis.

Cannabis-based medicines must be prescribed for an individual patient and dispensed through an authorised pharmacy.

How Does a UK Cannabis Clinic Work?

Procedures vary between providers, but a typical clinic pathway may include the following stages.

Initial Enquiry

The patient provides basic information about:

The diagnosed condition.
Current symptoms.
Previous treatment.
Medication history.
General eligibility.

An eligibility form does not guarantee acceptance or a prescription.

Medical Records

The clinic normally needs relevant medical information to confirm the diagnosis and review previous treatment.

This may include:

A Summary Care Record.
Specialist letters.
Medication history.
Test results.
Relevant mental-health information.

Specialist Consultation

An appropriately qualified clinician assesses the patient and discusses:

The condition and symptoms.
Treatments already attempted.
Potential risks and limitations.
Possible side effects.
Medication interactions.
Driving and impairment.
Monitoring requirements.

Prescribing Decision

The clinician may recommend treatment only where they consider it clinically appropriate.

Some clinics review new cases through a multidisciplinary team before confirming the decision.

Pharmacy Supply

If a prescription is issued, it is sent to an authorised pharmacy. The pharmacy completes the necessary checks and dispenses the medicine to the named patient.

Follow-Up Care

Ongoing monitoring may assess:

Changes in symptoms.
Adverse effects.
Medicine use.
Interactions.
Whether the treatment remains suitable.

What Can UK Cannabis Clinics Learn From Thailand?

Thailand and the United Kingdom have very different healthcare and legal systems. However, several broad lessons apply to both.

Regulation Should Develop Before Rapid Commercial Expansion

Thailand’s market expanded faster than its comprehensive retail framework.

When rules are unclear, businesses, patients and regulators may form different interpretations of what is permitted.

A stable medical system requires clear standards covering:

Who can prescribe.
Which patients may be considered.
How medicines are supplied.
How products are tested.
How clinics advertise.
How treatment is monitored.

Medical Access Should Remain Clinically Led

A medical cannabis service should begin with healthcare assessment rather than product selection.

Patients should not be encouraged to choose a cultivar or formulation before the clinician has reviewed their history and considered suitability.

The decision should be based on individual clinical circumstances, not consumer demand alone.

Advertising Requires Care

Advertising that presents medical cannabis as a lifestyle product can blur the distinction between healthcare and recreational retail.

Responsible clinic communication should avoid:

Guaranteed prescriptions.
Claims of universal eligibility.
Unsupported treatment claims.
Recreational imagery.
Pressure-based promotions.
Presenting prescriptions as ordinary online purchases.

Product Quality Must Be Consistent

Patients and clinicians require reliable information about prescribed medicines.

Quality systems may include:

Controlled cultivation.
Manufacturing standards.
Batch traceability.
Cannabinoid analysis.
Contaminant screening.
Stable pharmacy supply.

Rapid growth without consistent supply can lead to substitutions, stock shortages and disrupted treatment.

Patient Monitoring Is Essential

Issuing a prescription should not be the end of the clinical process.

Ongoing review helps identify:

Side effects.
Possible impairment.
Changes in mental health.
Medicine interactions.
Signs of dependence or misuse.
Whether treatment remains appropriate.

Why Regulatory Stability Matters to Patients

Patients need confidence that lawful treatment will remain accessible and properly supported.

Sudden regulatory changes can create:

Interrupted access.
Pharmacy delays.
Product substitutions.
Higher costs.
Uncertainty about prescriptions.
Confusion about lawful possession.

A sustainable system should be capable of responding to safety concerns without unnecessarily disrupting appropriately prescribed treatment.

Why Regulatory Stability Matters to Clinicians

Healthcare professionals require clear standards governing:

Eligibility.
Remote consultations.
Prescribing responsibility.
Multidisciplinary review.
Patient records.
Monitoring.
Adverse-event reporting.

Ambiguous rules may discourage clinicians from participating or lead to inconsistent practice between clinics.

Why Regulatory Stability Matters to Businesses

Clinics, pharmacies, cultivators and importers make long-term investments in:

Staff.
Clinical systems.
Premises.
Pharmacy capacity.
Stock.
Laboratory testing.
Compliance.

Thailand demonstrates the commercial consequences that can follow when businesses expand under one interpretation of policy before a lasting legal framework has been agreed.

Could UK Cannabis Clinics Face Tighter Regulation?

The future direction of UK policy cannot be predicted with certainty.

However, regulators may consider stronger controls if evidence emerges of:

Unsafe prescribing.
Inadequate access to medical records.
Insufficient mental-health assessment.
Misleading advertising.
Poor follow-up care.
Prescriptions issued without adequate clinical contact.
Failures in communication with NHS providers.

Stronger oversight would not necessarily end private medical cannabis access. It could instead establish more consistent clinical standards across the sector.

Recent UK Concerns About Private Clinics

The growth of private medical cannabis prescribing has attracted increasing public and regulatory attention.

Concerns reported in the UK have included:

Whether complete medical information was available before prescribing.
Communication between private clinics and NHS teams.
Assessment of patients with complex psychiatric histories.
Monitoring of adverse effects.
The suitability of high-THC medicines for vulnerable patients.

These concerns should not be used to suggest that all private prescribing is unsafe. They demonstrate why consistent governance and individual clinical assessment are necessary.

How Should Patients Assess a UK Cannabis Clinic?

Patients considering a private clinic may wish to review several factors before paying for an appointment.

Regulatory Status

Check whether the provider is registered with the appropriate healthcare regulator for its location and services.

Clinician Registration

Confirm that the prescribing clinician is registered with the relevant professional body and appropriately qualified for the treatment being considered.

Medical-Record Requirements

A responsible clinic should normally request sufficient medical information to make an informed prescribing decision.

Published Fees

The clinic should explain:

Initial consultation costs.
Follow-up fees.
Prescription charges.
Pharmacy costs.
Possible repeat-prescription fees.

Follow-Up Arrangements

Patients should understand how often reviews take place and who to contact if side effects or urgent concerns develop.

Pharmacy Information

The clinic should explain which authorised pharmacy will dispense the prescription and how delivery or collection works.

Realistic Communication

A clinic should not guarantee approval or claim that medical cannabis is proven to treat every condition.

Warning Signs When Researching a Cannabis Clinic

Potential warning signs include:

A guaranteed prescription before assessment.
No request for medical records.
Extremely brief consultations.
No discussion of risks or side effects.
Recreational or lifestyle-focused advertising.
No clear clinician information.
No follow-up process.
Prescriptions offered through anonymous messaging accounts.
Claims that treatment will cure a condition.

Can UK Cannabis Clinics Operate Online?

Many private clinics use remote consultations where this is considered clinically appropriate.

Telemedicine can improve access for:

Patients living in rural areas.
People with limited mobility.
Patients who struggle to travel.
People requiring regular follow-up.

Online consultation does not remove the clinician’s duty to conduct an appropriate assessment, verify information and arrange ongoing care.

Can Everyone Obtain a Medical Cannabis Prescription?

No. Medical cannabis is not automatically suitable for every patient or condition.

A clinician may decline to prescribe because:

The diagnosis is unclear.
Established treatments have not been adequately explored.
The evidence for the condition is limited.
There are significant interaction risks.
The patient’s physical or mental health history raises concerns.
The expected benefit does not outweigh the potential harm.

Is Medical Cannabis Available Through the NHS?

NHS prescriptions remain uncommon and are generally considered for a limited number of clinical circumstances.

These may include:

Certain rare and severe forms of epilepsy.
Multiple sclerosis-related spasticity in specified circumstances.
Chemotherapy-related nausea and vomiting where other medicines are unsuitable or ineffective.

Most patients accessing broader treatment currently do so through private clinics.

Medical Cannabis and Consumer Cannabinoids Are Different

Prescription cannabis-based medicinal products should not be confused with consumer cannabinoid products.

Medical Cannabis	Consumer Cannabinoid Products
Requires a patient-specific prescription.	Sold through ordinary retail channels where compliant.
Selected following clinical assessment.	Should not be presented as treating medical conditions.
Dispensed by an authorised pharmacy.	May include CBD, CBG and other hemp-derived formulations.
Requires medical monitoring.	Does not replace medical advice or prescribed treatment.
May include controlled cannabinoids under prescription.	Must comply with applicable controlled-cannabinoid requirements.

Weed Supermarket does not operate a medical cannabis clinic, issue prescriptions or provide personalised treatment recommendations.

Why Laboratory Standards Matter

Both prescription medicines and consumer cannabinoid products require reliable information about their composition.

Depending on the product and regulatory framework, laboratory assessment may include:

Cannabinoid profile.
Controlled cannabinoid concentration.
Heavy metals.
Pesticides.
Residual solvents.
Microbiological contamination.

Testing improves transparency but does not by itself demonstrate that a product is medically effective or suitable for an individual patient.

Read more in our UK Compliance & Laboratory Testing guide.

What Does Thailand Mean for the Future of UK Policy?

Thailand’s experience does not provide a direct prediction of what will happen in Britain.

It does demonstrate several principles:

Rapid commercial expansion can outpace regulation.
Unclear policy can create instability.
Medical language should not be used to disguise recreational retail.
Patient safeguards need to be established early.
Regulations should be clear enough for patients, clinicians and businesses to understand.
Sudden policy changes can create unintended consequences.

The UK has taken a more cautious route by retaining specialist prescribing and pharmacy control. The challenge is improving appropriate patient access without weakening clinical oversight.

Related Guides

Frequently Asked Questions

What is a UK cannabis clinic?

A UK cannabis clinic is a specialist healthcare service that assesses whether a patient may be suitable for treatment with a cannabis-based medicinal product.

Is medical cannabis legal in the UK?

Certain cannabis-based medicinal products may be prescribed by appropriately qualified specialist clinicians and dispensed through authorised pharmacies.

Can medical cannabis be prescribed online?

Some private clinics conduct remote consultations where telemedicine is considered clinically appropriate. An online appointment does not guarantee a prescription.

Can a GP prescribe medical cannabis?

Initiation is generally restricted to specialist doctors or clinicians acting within an appropriate specialist framework. A GP may still contribute medical records and coordinate other aspects of care.

Can medical cannabis be obtained through the NHS?

Yes, but NHS access remains limited and is generally associated with a small number of specific clinical circumstances.

What changed in Thailand?

Thailand introduced rules requiring a medical prescription for cannabis flower and strengthened licensing, sourcing and sales controls following rapid expansion after its 2022 decriminalisation policy.

Did Thailand completely ban cannabis?

No. Thailand moved towards a medical-only framework for cannabis flower rather than prohibiting every cannabis-related medical, research or industrial activity.

Why did thousands of Thai cannabis shops close?

Of 8,636 licences expiring during 2025, only 1,339 renewal applications were submitted. Many businesses chose not to continue under the tighter regulatory framework.

Could UK cannabis clinics be restricted in the future?

Future policy cannot be predicted. Regulators may strengthen oversight if evidence identifies unsafe prescribing, inadequate assessment or poor patient monitoring.

How can I check whether a clinic is reputable?

Review its regulatory registration, clinician credentials, medical-record process, fees, pharmacy arrangements, follow-up care and the accuracy of its advertising.

Is consumer CBD the same as prescribed medical cannabis?

No. Consumer cannabinoid products and patient-specific prescription medicines are separate product categories operating under different frameworks.

Does Weed Supermarket prescribe medical cannabis?

No. Weed Supermarket does not provide clinical consultations, issue prescriptions or operate a medical cannabis pharmacy.

Final Thoughts

Thailand’s rapid cannabis expansion and subsequent medical-only reset demonstrate how difficult it can be to create a stable market after commercial activity has already grown beyond the original policy framework.

The lesson for the UK is not that patient access should be prevented. It is that access should be built around qualified clinicians, appropriate assessment, reliable pharmacy supply, product quality and continuing patient monitoring.

UK cannabis clinics can improve access for patients who may not otherwise reach specialist care. However, convenience and commercial growth should never replace clinical judgement or patient safety.

A clear, stable and evidence-led framework provides the strongest foundation for patients, healthcare professionals and the long-term credibility of medical cannabis treatment.

Compliance Statement

This article is provided for educational, healthcare-policy and legal-awareness purposes only. It does not assess eligibility for medical cannabis, recommend treatment or provide personalised medical advice. Cannabis-based medicinal products must be prescribed by an appropriately qualified clinician and supplied through lawful pharmacy channels. Consumer cannabinoid products are not substitutes for prescribed medicines. Never start, stop or change medication without consulting the healthcare professional responsible for your care.